biostudies-literatureTseng TCNational Taiwan University HospitalMinistry of Science and Technology, TaiwanMinistry of Health and Welfare589-606https://www.ebi.ac.uk/biostudies/studies/S-EPMC9925660biostudies-literatureUnknown12(2)<h4>Introduction</h4>High-dose daptomycin-based combinations are recommended for vancomycin-resistant Enterococcus (VRE) bloodstream infection (BSI). Preclinical data have shown a synergistic effect of daptomycin/fosfomycin combinations against VRE. However, clinical studies comparing daptomycin monotherapy with daptomycin/fosfomycin combinations are unavailable.<h4>Methods</h4>An observational study of VRE-BSI was performed between 2010-2021 on patients receiving daptomycin monotherapy (≥ 8 mg/kg) or daptomycin combined with intravenous fosfomycin. Patients treated with concomitant β-lactam combinations were excluded. The primary outcome was in-hospital mortality. Outcomes were analyzed using multivariable logistic regression and augmented inverse probability weighting (AIPW) analyses.<h4Infectious diseases and therapyThe Combination of Daptomycin with Fosfomycin is More Effective than Daptomycin Alone in Reducing Mortality of Vancomycin-Resistant Enterococcal Bloodstream Infections: A Retrospective, Comparative Cohort Study.PMC9925660NTUH. 110-S4901111-2314-B-002-209110-2326-B-002-003-MY3110-2628-B-002-059MOHW111-TDU-B-211-134002Chang SCTseng TCWang JTChen YCHuang SHChuang YCYang JLLin CYfalseThe Combination of Daptomycin with Fosfomycin is More Effective than Daptomycin Alone in Reducing Mortality of Vancomycin-Resistant Enterococcal Bloodstream Infections: A Retrospective, Comparative Cohort Study.<h4>Introduction</h4>High-dose daptomycin-based combinations are recommended for vancomycin-resistant Enterococcus (VRE) bloodstream infection (BSI). Preclinical data have shown a synergistic effect of daptomycin/fosfomycin combinations against VRE. However, clinical studies comparing daptomycin monotherapy with daptomycin/fosfomycin combinations are unavailable.<h4>Methods</h4>An observational study of VRE-BSI was performed between 2010-2021 on patients receiving daptomycin monotherapy (≥ 8 mg/kg) or daptomycin combined with intravenous fosfomycin. Patients treated with concomitant β-lactam combinations were excluded. The primary outcome was in-hospital mortality. Outcomes were analyzed using multivariable logistic regression and augmented inverse probability weighting (AIPW) analyses.<h42023-01-01T00:00:00Z2023 Feb2025-04-04T12:41:50.811Z2025-04-04T12:41:50.811ZS-EPMC99256603662999710.1007/s40121-022-00754-1